Clinical overview of promising nonthienopyridine antiplatelet agents

Am Heart J. 2008 Aug;156(2 Suppl):S23-8. doi: 10.1016/j.ahj.2008.06.006.

Abstract

Three novel nonthienopyridine antiplatelet agents--cangrelor, ticagrelor (AZD6140), and SCH 530348--are in advanced clinical testing in patients with coronary artery disease. Cangrelor and ticagrelor are direct and reversible inhibitors of the platelet adenosine 5'-diphosphate P2Y12 receptor, whereas SCH 530348 is a thrombin receptor antagonist. Clinical data available to date for each of these compounds suggest that they have safety and efficacy profiles that will be advantageous to patients with acute coronary syndromes or undergoing percutaneous intervention. We review the clinical features of these new platelet inhibition therapies.

Publication types

  • Review

MeSH terms

  • Acute Coronary Syndrome / drug therapy*
  • Adenosine / analogs & derivatives*
  • Adenosine / therapeutic use
  • Adenosine Monophosphate / analogs & derivatives*
  • Adenosine Monophosphate / therapeutic use
  • Angioplasty, Balloon, Coronary
  • Aspirin / therapeutic use
  • Clinical Trials as Topic
  • Coronary Disease / drug therapy*
  • Coronary Disease / therapy
  • Drug Therapy, Combination
  • Humans
  • Lactones / therapeutic use*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Purinergic P2 Receptor Antagonists
  • Pyridines / therapeutic use*
  • Receptors, Thrombin / antagonists & inhibitors
  • Ticagrelor

Substances

  • Lactones
  • Platelet Aggregation Inhibitors
  • Purinergic P2 Receptor Antagonists
  • Pyridines
  • Receptors, Thrombin
  • Adenosine Monophosphate
  • cangrelor
  • Ticagrelor
  • Adenosine
  • Aspirin
  • vorapaxar